111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging

@article{Bombardieri2010111InpentetreotideSP,
  title={111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging},
  author={Emilio Bombardieri and Valentina Ambrosini and Cumali Aktolun and Richard P Baum and Angelica Bishof-Delaloye and Silvana del Vecchio and Lorenzo Stefano Maffioli and Luc A. Mortelmans and Wim J. G. Oyen and Giovanna Pepe and Arturo Chiti},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2010},
  volume={37},
  pages={1441-1448}
}
This document provides general information about somatostatin receptor scintigraphy with 111In-pentetreotide. This guideline should not be regarded as the only approach to visualise tumours expressing somatostatin receptors or as exclusive of other nuclear medicine procedures useful to obtain comparable results. The aim of this guideline is to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of 111In-pentetreotide scintigraphy. 
Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE
The aim of these guidelines is to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin (SST) receptor PET/CT imaging using
Radionuclide Imaging (SPECT)
TLDR
The role of radiopharmaceuticals available for planar scintigraphy and single photon emission computed tomography (SPECT) in NET imaging is discussed, highlighting their advantages and limitations.
Contribution of 111In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours
TLDR
SPECT/CT provides incremental diagnostic value over SRS, mainly because of a precise anatomical localization that helps discriminate between tumour lesions and physiological uptake, and may detect unsuspected lesions in a small proportion of patients.
A potentially misleading finding at somatostatin receptor scintigraphy: Focal pulmonary areas of intense accumulation without computed tomography-detectable lung lesions
TLDR
This case shows that pulmonary In-111 pentetreotide uptake without evidence of a macroscopic lesion is shown, and non-specific areas of increased accumulation can result from non- specific uptake of the radiopeptide, of its related catabolites and complexes and other in vivo-produced radiochemical forms.
Nuclear Medicine Imaging in Neuroendocrine Tumors
TLDR
FDG-PET has prognostic information that potentially may be used in selection of therapy and the need for 123I-MIBG, 18F-DOPA, and 11C-5-HTP may be limited.
Metastatic neuroendocrine carcinoma presenting as a "Superscan" on 68Ga-DOTANOC somatostatin receptor PET/CT.
TLDR
An elderly man with pancreatic neuroendocrine tumor with confirmed liver metastases underwent restaging Ga-DOTANOC PET/CT to monitor response to cold octreotide therapy and showed an increase in number and uptake of the metastatic lesions suggestive of progressive disease resulting in the appearance of a superscan.
Pitfalls and Limitations of Radionuclide Imaging in Endocrinology.
TLDR
Several different techniques, radiopharmaceuticals, and imaging modalities are commonly used in nuclear medicine for studies of endocrine organs for accurate diagnosis and patient management.
Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors
TLDR
Radionuclides are needed both for nuclear medicine imaging as well as for peptide-receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NET) and somatostatin receptor PET at hand, where FDG-PET is well suited for visualization of most of the somatstatin receptor-negative tumors prognostic in NET patients.
111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden
TLDR
SSTR PET results in higher Krenning scores than 111In-pentetreotide, particularly when lesions measured 2 cm or less, which cannot be directly applied to patients with small lesions.
The SNM Practice Guideline for Somatostatin Receptor Scintigraphy 2.0*
TLDR
This activity has been approved for 1.0 VOICE (Category A) credit and participants can access this activity on page 325 or on the SNM Web site (http://www.snm.org/ce_online) through December 31, 2013.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 69 REFERENCES
[Somatostatin receptor scintigraphy].
Somatostatin receptor scintigraphy (SRS) is a very valuable imaging technique for visualisation of a diversity of neuroendocrine tumours. The sensitivity for localisation of carcinoid tumours is
SPECT/CT hybrid imaging with 111In‐pentetreotide in assessment of neuroendocrine tumours
TLDR
The impact of sequentially performed single‐photon emission computed tomography (SPECT)/CT fusion on SRS study interpretation and clinical management of neuroendocrine tumours is evaluated.
Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors.
TLDR
In 85 patients with GEP tumors or after operative removal of such tumors, receptor scintigraphy proved to be superior to ultrasound and computed tomography in 34%, equal in 52%, and inferior in 14% of the cases.
Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide.
TLDR
It is concluded that somatostatin receptor scintigraphy using [111In-DTPA-D-Phe1]-octreotide has a future role in the staging of patients with carcinoid disease.
Octreoscan radioreceptor imaging
TLDR
Octreoscan® is a radiopharmaceutical with proven clinical importance in the visualization of somatostatin-receptor-positive tumors, and the overall sensitivity of som atostatin receptor imaging is high.
Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies
TLDR
The role of SRS in post‐treatment surveillance of PBTs is evaluated and, as a functional imaging modality, may be better able to differentiate tumor from scar/necrosis.
Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide.
TLDR
This research presents a novel and scalable approach to regenerative medicine that addresses the underlying cause of central giant cell granuloma, which is a leading cause of cancer in women.
Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan).
TLDR
The success of somatostatin receptor imaging in evaluating patients with suspected neuroendocrine tumors, including identifying otherwise radiographically occult lesions, has resulted in ranking somatosteroid receptor imaging as the prime imaging procedure in patients with suspicion of neuro endocrine tumors at The Ohio State University.
Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours.
TLDR
The results with somatostatin receptor imaging in neuroendocrine tumours of the gastro-entero-pancreatic tract demonstrate that all figures of merit are excellent when imaging is accurately performed and analysed by experienced operators.
Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview
TLDR
The overall sensitivity of [111In-DTPA-D-Phe1]-octreotide scintigraphy to localize neuroendocrine tumors is high and inclusion of somatostatin receptor imaging in the localization or staging procedure may be very rewarding, either in terms of cost-effectiveness, patient management, or quality of life.
...
1
2
3
4
5
...